健帆生物
(300529)
| 流通市值：77.99亿 | | | 总市值：121.55亿 |
| 流通股本：5.12亿 | | | 总股本：7.99亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,032,473,665.31 | 560,623,604.23 | 2,011,817,980.59 | 1,556,021,993.54 |
| 营业收入 | 1,032,473,665.31 | 560,623,604.23 | 2,011,817,980.59 | 1,556,021,993.54 |
| 二、营业总成本 | 596,082,381.08 | 307,800,952.25 | 1,338,531,874.32 | 1,020,308,100.76 |
| 营业成本 | 222,436,553.93 | 127,540,788.3 | 428,504,854.51 | 317,573,999.79 |
| 税金及附加 | 19,162,950.66 | 11,058,515.16 | 36,789,929.28 | 27,585,735.8 |
| 销售费用 | 161,863,474.34 | 84,090,850.36 | 501,486,134.05 | 382,811,804.6 |
| 管理费用 | 70,775,982.46 | 31,325,955.98 | 131,661,596.44 | 114,569,886.31 |
| 研发费用 | 103,092,779.17 | 45,687,935.29 | 198,445,264.14 | 147,028,910.64 |
| 财务费用 | 18,750,640.52 | 8,096,907.16 | 41,644,095.9 | 30,737,763.62 |
| 其中:利息费用 | 24,780,525.46 | 12,354,915.58 | 53,511,826.05 | 40,234,062.71 |
| 其中:利息收入 | 9,460,289.5 | 5,438,922.4 | 14,471,550.8 | 10,506,736.68 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 18,816,274.42 | 9,488,846.85 | 11,065.14 | 30,921,869.97 |
| 加:投资收益 | 5,861,735.34 | 823,041.03 | 53,475,879.1 | 8,748,220.88 |
| 资产处置收益 | -113,195.9 | -47,499.57 | -79,851.27 | -2,843,064.1 |
| 资产减值损失(新) | -19,992,055.68 | -7,132,002.36 | -63,877,891.55 | -8,261,933.67 |
| 信用减值损失(新) | -1,576,059.33 | -1,613,136.25 | 3,379,518.23 | 3,151,415.44 |
| 其他收益 | 12,666,678.39 | 6,874,287.31 | 24,591,650.71 | 18,950,231.78 |
| 四、营业利润 | 452,054,661.47 | 261,216,188.99 | 690,786,476.63 | 586,380,633.08 |
| 加:营业外收入 | 59,818.46 | 4,562.73 | 15,521,805.99 | 838,449.95 |
| 减:营业外支出 | 4,981,208.85 | 1,206,098.49 | 46,181,185.46 | 35,165,220.08 |
| 五、利润总额 | 447,133,271.08 | 260,014,653.23 | 660,127,097.16 | 552,053,862.95 |
| 减:所得税费用 | 64,144,363.61 | 39,366,916.86 | 128,455,918.27 | 100,195,513.49 |
| 六、净利润 | 382,988,907.47 | 220,647,736.37 | 531,671,178.89 | 451,858,349.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 382,988,907.47 | 220,647,736.37 | 531,671,178.89 | 451,858,349.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 381,968,997.2 | 220,512,869.14 | 532,821,312.26 | 453,230,155.4 |
| 少数股东损益 | 1,019,910.27 | 134,867.23 | -1,150,133.37 | -1,371,805.94 |
| 扣除非经常损益后的净利润 | 355,390,817.98 | 207,916,690.53 | 512,932,081.32 | 438,090,907.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.49 | 0.28 | 0.69 | 0.59 |
| (二)稀释每股收益 | 0.48 | 0.28 | 0.69 | 0.57 |
| 八、其他综合收益 | - | - | 2,799,145.61 | - |
| 归属于母公司股东的其他综合收益 | - | - | 2,799,145.61 | - |
| 九、综合收益总额 | 382,988,907.47 | 220,647,736.37 | 534,470,324.5 | 451,858,349.46 |
| 归属于母公司股东的综合收益总额 | 381,968,997.2 | 220,512,869.14 | 535,620,457.87 | 453,230,155.4 |
| 归属于少数股东的综合收益总额 | 1,019,910.27 | 134,867.23 | -1,150,133.37 | -1,371,805.94 |
| 公告日期 | 2026-08-07 | 2026-04-28 | 2026-04-28 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |